ID   PFI-285
AC   CVCL_A664
DR   Cosmic; 1086320
DR   Wikidata; Q54947253
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2307225;
RX   PubMed=8558920;
CC   Doubling time: ~24 hours (PubMed=2307225).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C3466; T-cell non-Hodgkin lymphoma
DI   ORDO; Orphanet_171918; T-cell non-Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 9
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2307225; DOI=10.1111/j.1600-0609.1990.tb00340.x;
RA   Helgestad J., Pettersen R., Storm-Mathisen I., Schjerven L.,
RA   Ulrich K., Smeland E.B., Egeland T., Sorskaard D., Brogger A.,
RA   Hovig T., Degre M., Lie S.O.;
RT   "Characterization of a new malignant human T-cell line (PFI-285)
RT   sensitive to ascorbic acid.";
RL   Eur. J. Haematol. 44:9-17(1990).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//